NCT04554771View on ClinicalTrials.gov

Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

October 10, 2022

Study Completion Date

April 10, 2028

Conditions
Esophageal AdenocarcinomaOesophageal AdenocarcinomaResectable Carcinoma
Interventions
DRUG

Tocilizumab 20 Mg/mL Intravenous Solution

tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 of standard of care neoadjuvant chemoradiation

DRUG

Paclitaxel

Paclitaxel 50 mg/m2 will be given intravenously on days 1, 8, 15, 22 and 29

DRUG

Carboplatin

Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29

RADIATION

External beam radiotherapy

External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy

Trial Locations (1)

1100 DD

Academic Medical Center, Medical Oncology, Amsterdam

All Listed Sponsors
collaborator

Noordwest Ziekenhuisgroep

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER